Investing
AstraZeneca signs $2 billion agreement with Quell to develop cell therapies
© Reuters. FILE PHOTO: FILE PHOTO: Test tubes are seen in front of a displayed AstraZeneca logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration
(Reuters) – AstraZeneca (NASDAQ:) said on Friday it had signed an agreement with Quell Therapeutics potentially worth more than $2 billion to develop cell therapies that could cure autoimmune diseases.
The agreement includes developing, manufacturing and commercialising cell therapies that have the potential to be curative in type 1 diabetes and inflammatory bowel disease indications, the drugmaker said in a statement.
UK-based Quell will receive $85 million upfront from AstraZeneca, and is also eligible to receive over $2 billion for further development and commercialisation milestones, the company added.
Read the full article here
-
Passive Income7 days ago
Are You Running Your Business, or Is Your Business Running You?
-
Side Hustles7 days ago
How Your Body Language Can Help Win a Disagreement
-
Side Hustles6 days ago
How to Be Unapologetically You and Why It Matters
-
Side Hustles7 days ago
OpenAI Raises Record $6.6 Billion, Adds 50 Million New Users
-
Side Hustles6 days ago
With AI Magicx, It’s Like Getting an Entire Creative Team in One Money-Saving AI Tool
-
Investing7 days ago
7 Marketing Strategies to Help Your Startup Grow and Scale
-
Investing5 days ago
Nvidia CEO Jensen Huang: Demand For Blackwell AI Is Insane
-
Side Hustles5 days ago
Mark Zuckerberg Is Now Second Richest Person in the World